Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On ...

Using principles from applied game theory, options traders may have an intriguing opportunity with TEVA stock.

Teva Pharmaceutical Industries will release its Q2 2025 financial results on July 30, 2025, with a conference call following.

According to Benzinga Pro, Teva Pharmaceutical Indus's peer group average for short interest as a percentage of float is 3.59 ...

News about Teva Pharmaceutical Industries Ltd., including commentary and archival articles published in The New York Times.

Review the current Teva Pharmaceutical Industries Ltd ADR (TEVA:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if TEVA is the best investment for ...

Find the latest Teva Pharmaceutical Industries Limited (TEVA) stock quote, history, news and other vital information to help you with your stock trading and investing.

Avendran Naidu appointed Head of Commercial to lead new affiliateCNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® ...

Stay up to date on Teva Pharmaceutical Indus analyst ratings. About Teva Pharmaceutical Indus Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world.

Teva Pharmaceutical Industries Limited (TEVA) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.